Human Stromal Cell-Derived Factor-1 alpha Recombinant

Catalog #
90237-B
$205 *
Size: 10 µg
Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

Recombinant SDF-1 alpha is a disulfide-linked monomer protein consisting of 69 amino acid residues, migrates as an approximately 8 kDa protein under non-reducing and reducing conditions in SDS-PAGE. Optimized DNA sequence encoding human Stromal Cell-Derived Factor-1 alpha was expressed in E. coli.

Synonyms
Stromal Cell-Derived Factor-1 alpha, SDF1a, CXCL12, TLSF-A, SCDF-1
Product Info
Storage and Usage
Citations
Species
Human
Host Species/Expression System
E. coli
Purity
≥97% by SDS-PAGE and HPLC
Format
lyophilized protein
Formulation
Lyophilized from a 0.2 µm filtered concentrated (1 mg/ml) solution in 20 mM phosphate buffer, pH 7.2.
MW
8 kDa
Endotoxin Level
<0.1 ng/µg (1 EU/µg), using the LAL gel clot method.
Amino Acids
22–89
Biological Activity
Determined by its ability to chemoattract human peripheral T cells activated with PHA and IL-2 using a concentration range of 10-40 ng/ml.
Genbank #
P48061
UniProt #
P48061
Background
SDF-1alpha and SDF-1beta are small cytokines belonging to the CXC- Chemokines. SDF-1 is identical with a chemokine reported to function as a pre-B-cell growth factor in the presence of IL-7 and isolated originally from a murine bone marrow stromal cell line. Human SDF-1alpha and SDF-1beta are encoded by a single gene and arise by alternative splicing. SDF-1 acts on lymphocytes and monocytes but not neutrophils in vitro and is a highly potent chemoattractant for mononuclear cells in vivo. In addition, SDF-1 also induces intracellular actin polymerization in lymphocytes. SDF acts as a chemoattractant for human hematopoietic progenitor cells expressing CD34 giving rise to mixed types of progenitors, and more primitive types. The chemotactic response is inhibited by pertussis toxin. Chemotaxis of CD34(+) cells in response to SDF is increased by IL-3 in vitro. SDF has been shown also to induce a transient elevation of cytoplasmic calcium in these cells.
References
1. Hiesinger W, et al. Trends Cardiovasc Med. 2012 Aug,22(6):139-44.
2. Felix AS, et al. Cancer Microenviron. 2010 Feb 26,3(1):49-56.